KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Convertible Debt (2016 - 2025)

Pacira BioSciences has reported Convertible Debt over the past 13 years, most recently at $280.3 million for Q2 2025.

  • For Q2 2025, Convertible Debt fell 41.56% year-over-year to $280.3 million; the TTM value through Jun 2025 reached $280.3 million, down 41.56%, while the annual FY2024 figure was $279.3 million, 29.92% down from the prior year.
  • Convertible Debt for Q2 2025 was $280.3 million at Pacira BioSciences, roughly flat from $279.8 million in the prior quarter.
  • Over five years, Convertible Debt peaked at $479.5 million in Q2 2024 and troughed at $278.9 million in Q3 2024.
  • A 5-year average of $362.0 million and a median of $397.7 million in 2023 define the central range for Convertible Debt.
  • Biggest five-year swings in Convertible Debt: increased 26.97% in 2022 and later tumbled 41.56% in 2025.
  • Year by year, Convertible Debt stood at $339.3 million in 2021, then grew by 19.31% to $404.8 million in 2022, then decreased by 1.53% to $398.6 million in 2023, then fell by 29.92% to $279.3 million in 2024, then grew by 0.33% to $280.3 million in 2025.
  • Business Quant data shows Convertible Debt for PCRX at $280.3 million in Q2 2025, $279.8 million in Q1 2025, and $279.3 million in Q4 2024.